Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


3 Healthcare Stocks That Fall Short

2026-09-14
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.

Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2026-09-14

Revvity to Acquire Human Cell Design to Boost Metabolic Discovery

2026-09-11
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.

These S&P500 stocks are gapping in today's session

2026-09-09
Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

2026-09-09

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

2026-09-09
WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin

UBS Assumes Revvity at Neutral, Raises Price Target to $140

2026-09-09
UBS analyst Doug Schenkel assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.

Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition

2026-09-09
Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.

Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases

2026-09-09
 The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other

Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others

2026-09-08
500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro